ライフサイエンスコーパス: clear cell

1 carcinoma histotypes (serous, endometrioid, clear cell).

2 Rlog2 = 1.40 (1.03-1.91)], but not serous or clear cell.

3 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other).

4 stoma) and 68 malignant masses (including 41 clear cell, 20 papillary, and seven chromophobe renal ce

5 urgery, 152 renal tumors were identified (77 clear cell, 22 papillary, 18 chromophobe, and 10 unclass

6 quently develop vaginal adenosis, from which clear cell adenocarcinoma can arise.

7 Her medical history was significant for clear cell adenocarcinoma of the endometrium.

8 haracteristics (eg, endometrioid, serous, or clear-cell adenocarcinoma).

9 optimal threshold for discriminating between clear cell and papillary RCC renal cell carcinoma , and

10 he optimal threshold to discriminate between clear cell and papillary RCC renal cell carcinoma , and

11 ification can be used to distinguish between clear cell and papillary RCC renal cell carcinoma , and

12 marker in ccRCC that can distinguish between clear cell and papillary subtypes.

13 ), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous, including 23,235

14 croarrays containing 42 dedifferentiated, 23 clear cell, and 23 mesenchymal chondrosarcomas and perfo

15 The mesenchymal, clear cell, and dedifferentiated chondrosarcoma subtypes

16 nd low grade serous, endometrioid, mucinous, clear cell, and granulosa cell carcinomas and in precurs

17 ring by risk factors separated endometrioid, clear cell, and low-grade serous carcinomas from high-gr

18 is-related tumors that include endometrioid, clear cell, and seromucinous carcinomas; ii) low-grade s

19 ad unusual histologies (pleomorphic, myxoid, clear cell, and signet ring cell).

20 Clear cell cancer is an important example.

21 Clear cell cancer of the ovary is now recognized as a un

22 support for a unique clinical management of clear cell cancer of the ovary.

23 Recent work has shown that a subset of clear cell cancers evolve from endometriosis.

24 Molecular alterations within clear cell cancers include unique cytokine expression pa

25 Further, we found no mutations typical of clear cell carcinoma (Arid1a, Pik3ca), low-grade serous

26 ack of current treatment options for ovarian clear cell carcinoma (CCC) and the cancer is often resis

27 s are rarely present at diagnosis of ovarian clear cell carcinoma (OCC).

28 Ovarian clear cell carcinoma (OCCC), a very aggressive subtype,

29 sis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune ge

30 Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of

31 71) and the Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma data set (n=413).

32 alphavbeta3 expression by tumor cells in the clear cell carcinoma group.

33 Concurrent thyroid metastasis of clear cell carcinoma is uncommon but it can appear as a

34 rom The Cancer Genome Atlas program's Kidney Clear Cell Carcinoma project.

35 Clear cell carcinoma showed the strongest genetic correl

36 carcinoma (ccRCC, also known as kidney renal clear cell carcinoma), papillary (pRCC, also known as ki

37 s review will describe the unique biology of clear cell carcinoma, its novel molecular features, and

38 et driving the aggressive phenotype in renal clear cell carcinoma.

39 been removed eight years earlier because of clear cell carcinoma.

40 s carcinomas but at low frequency in ovarian clear cell carcinoma.

41 Ovarian clear-cell carcinoma (OCCC) is an aggressive form of ova

42 84 with endometrioid carcinoma, and 390 with clear-cell carcinoma.

43 ependence and specific protein expression in clear-cell carcinoma.

44 The subtypes of RCC were as follows: clear cell carcinomas (n=23), papillary carcinomas (n=6)

45 cy also occurs in poor prognosis endometrial clear cell carcinomas and has some association with endo

46 ly, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently have no effective

47 The majority of kidney cancers are clear-cell carcinomas (ccRCC), characterized by the accu

48 invasive serous, mucinous, endometrioid, or clear-cell carcinomas of the ovary.

49 Although these analyses included only 30 clear-cell carcinomas, results suggest that loss of expr

50 Histopathological diagnosis was renal clear cell carinoma.

51 methylation class mainly represented by the clear-cell cases (20 clear cell out of 23 cases) had imp

52 d a propensity toward hypermethylation among clear-cell cases.

53 erogeneous uptake patterns are observed with clear cell-cell variations in tumor xenograft tissues, n

54 Patients with metastatic RCC, with a clear cell component, prior nephrectomy, measurable dise

55 three ccRCC epigenetic clusters, including a clear cell CpG island methylator phenotype (C-CIMP) subg

56 e, induced by low doses of cytotoxic agents, clears cell debris.

57 HNF1B is overexpressed in clear cell epithelial ovarian cancer, and we observed ep

58 s in HNF1B associate with risk of serous and clear cell epithelial ovarian cancer; DNA methylation an

59 cell line categories: epithelial (group I), clear cell (group II) and mesenchymal (group III).

60 m individuals with SMARCE1 mutations were of clear-cell histological subtype, and all had loss of SMA

61 nd Obstetrics [FIGO] stage I-IIa, grade 3 or clear cell histology) or more advanced disease (FIGO sta

62 ogenesis of both meningiomas and tumors with clear-cell histology.

63 ified through The Cancer Genome Atlas (TCGA) clear cell kidney (KIRC) dataset (419 white and 19 Afric

64 high incidence of mTOR mutations observed in clear cell kidney cancer, where VHL loss and HIF activat

65 Focusing on breast and clear-cell kidney tumors, we report the existence of key

66 tain histotypes of ovarian cancer, including clear cell, low-grade serous and endometrioid carcinomas

67 his multicentre phase 3 study, patients with clear cell metastatic renal cell carcinoma who received

68 Eligible patients had clear cell metastatic renal cell carcinoma, progressive

69 , patients with treatment-naive, measurable, clear-cell metastatic renal-cell carcinoma from 13 count

70 We randomly assigned 1110 patients with clear-cell, metastatic renal-cell carcinoma, in a 1:1 ra

71 and Methods Eligible patients had untreated clear cell mRCC and Eastern Cooperative Oncology Group p

72 s and Methods Patients with treatment-naive, clear cell mRCC were treated with four cycles of sunitin

73 Patients with clear-cell mRCC previously treated with agents targeting

74 tiated May 31, 2011, including patients with clear-cell mRCC previously treated with antiangiogenic t

75 ents with previously untreated predominantly clear-cell mRCC were randomly assigned, stratified by pr

76 Patients with clear-cell mRCC who progressed on or after vascular endo

77 IFN/bevacizumab for first-line treatment in clear-cell mRCC.

78 ession in transgenic mice, resulted in renal clear cells, multi-layered basement membranes, severe cy

79 , function in a quality control mechanism to clear cells of incompletely 5' end-capped messenger RNAs

80 hat intracellular Ca2+ release by InsP3R2 in clear cells of the sweat glands is important for eccrine

81 cell carcinoma (RCC) specimens (chromophobe, clear cell, oncocytoma, papillary type 1, and papillary

82 ific diagnostic and screening biomarkers for clear cell or papillary RCC and in the differential diag

83 (57 men, 31 women) with diagnosis of either clear cell or papillary RCC renal cell carcinoma at path

84 noninvasive biomarkers to diagnose malignant clear cell or papillary renal cell carcinoma (RCC) in a

85 ed no significant associations for mucinous, clear-cell, or low-grade serous carcinoma.

86 inly represented by the clear-cell cases (20 clear cell out of 23 cases) had improved survival time.

87 onfirmed the association between rs17561 and clear cell ovarian cancer [OR, 0.84; 95% confidence inte

88 helial cells (EECs), the likely precursor of clear cell ovarian carcinomas (CCOCs).

89 As increasing evidence indicates that clear-cell ovarian cancer may have unique pathogenesis,

90 We identified a clear-cell ovarian cancer tumor methylation profile (n =

91 To study epigenetics in clear-cell ovarian cancer, fresh frozen tumor DNA (n = 4

92 The mean ER of clear cell, papillary and chromophobe RCC were 188+/-49.

93 The mean WR of clear cell, papillary and chromophobe RCCs were 28.6+/-6

94 glycogen accumulation, and acquisition of a clear cell phenotype in Vhl-deficient renal epithelial c

95 Rather than being a passive bystander, the clear-cell phenotype is suggested to be a biomarker of d

96 d successfully in the glioblastoma and renal clear cell projects of The Cancer Genome Atlas program.

97 L/min/100 g +/- 15.1) was lower than that of clear cell RCC (171.6 mL/min/100 g +/- 61.2, P = .001),

98 r suppressor that is lost in the majority of clear cell RCC (ccRCC) cases.

99 Clear cell RCC (ccRCC) showed more intense contrast enha

100 (FSTL1) was significantly down-regulated in clear cell RCC (ccRCC), in particular metastatic ccRCC.

101 whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the dise

102 erations found in human papillary (pRCC) and clear cell RCC (ccRCC), the most common RCC subtypes.

103 fusion of oncocytoma was higher than that of clear cell RCC (P < .001).

104 nce in ER (P=0.001) and WR (P=0.001) between clear cell RCC and other subtypes of RCC.

105 thesis-generating study of 233 patients with clear cell RCC and waived the informed consent requireme

106 ns formation were pointed out as a potential clear cell RCC biomarkers.

107 The genotype of solid clear cell RCC differed significantly from the genotype

108 sion parameters useful in differentiation of clear cell RCC from chromophobe and papillary RCCs.

109 lidated, may assist in the discrimination of clear cell RCC from oncocytoma, papillary RCC, and chrom

110 olding of enhancement helped to discriminate clear cell RCC from oncocytoma, papillary RCC, and chrom

111 values of ER and WR used for differentiating clear cell RCC from other subtypes of RCC were 142 and 3

112 interesting new approach in the treatment of clear cell RCC is antibody-mediated therapy with the chi

113 ly decreased uptake of (111)In-girentumab in clear cell RCC lesions.

114 Pathological result was reported as clear cell RCC metastasis.

115 2)-kinase (JNK), is selectively activated in clear cell RCC patient specimens.

116 (111)In-girentuximab uptake in the tumor in clear cell RCC patients, especially in the group treated

117 This preliminary radiogenomics analysis of clear cell RCC revealed associations between CT features

118 ogic fidelity, these models of papillary and clear cell RCC should be significant contributions to th

119 d-lower pole of the left kidney diagnosed as clear cell RCC with vascular invasion, liver, lung and b

120 In clear cell RCC, increased emphasis is being placed on ta

121 , KDM5C, and BAP1 were absent in multicystic clear cell RCC, mutations of VHL (P = .016) and PBRM1 (P

122 In clear cell RCC, VHL loss generates pseudohypoxia that ex

123 gnificantly from the genotype of multicystic clear cell RCC.

124 ) were significantly more common among solid clear cell RCC.

125 diameter and enhancement parameters of each clear cell RCC.

126 ess can also be valid therapeutic targets in clear cell RCC.

127 of these novel manifestations of paediatric clear cell RCC.

128 help explain the pathologic cooperativity in clear-cell RCC between PTEN inactivation and pVHL loss,

129 -1 expression is a poor prognostic factor in clear-cell RCC that is associated with activation of an

130 tients with digital CT images and metastatic clear-cell RCC treated with sunitinib were included (n =

131 candidate biomarker and tumor suppressor in clear-cell RCC.

132 m 108 pathologically proved renal masses (88 clear cell RCCs and 20 minimal fat AMLs from 64 men and

133 Mean enhancement of clear cell RCCs and oncocytomas peaked in the corticomed

134 Enhancement of clear cell RCCs was greater than that of chromophobe RCC

135 Enhancement of clear cell RCCs was greater than that of oncocytomas in

136 Enhancement of clear cell RCCs was greater than that of papillary RCCs

137 Mutation frequencies among clear cell RCCs were as follows: VHL, 53.2% (124 of 233)

138 ently reviewed pretreatment CT images of all clear cell RCCs without knowledge of their genomic profi

139 A total of 170 clear cell RCCs, 57 papillary RCCs, 49 oncocytomas, and

140 d in and drives the growth of pVHL-deficient clear cell RCCs.

141 nts with high-risk (pT3, pT4, node-positive) clear cell renal cancer (ccRCC) in the ASSURE trial (adj

142 ognised as necessary for the pathogenesis of clear cell renal cancer (ccRCC); however, the molecular

143 etermine the phenotypes of isogenic pairs of clear cell renal cancer cells (ccRCC), with or without V

144 reviously untreated patients with metastatic clear cell renal cancer recruited between June 2008 and

145 reviously untreated patients with metastatic clear cell renal cancer.

146 n patients with intermediate-risk metastatic clear cell renal cancer.

147 In clear cell renal carcinoma (CCRC), hypoxic signaling is

148 XBSeq2 by using a set of in-house generated clear cell renal carcinoma (ccRCC) samples.

149 is an archetypical tumor-initiating event in clear cell renal carcinoma (ccRCC) that leads to the act

150 in VHL disease, congenital polycythaemia and clear cell renal carcinoma (ccRCC).

151 ed the anti-tumor effect of MLN4924 in human clear cell renal carcinoma (ccRCC).

152 rt a case of a 56-year-old male patient with clear cell renal carcinoma confirmed on a histopathologi

153 1a in seven cases and pT1b in one case (five clear cell renal carcinoma, two chromophobe type, and on

154 Most clear cell renal carcinomas (ccRCCs) are initiated by so

155 Clear cell renal carcinomas (ccRCCs) can display intratu

156 s mutated in diverse tumour types, including clear cell renal carcinomas (ccRCCs).

157 e at risk of developing multiple independent clear cell renal carcinomas.

158 Clear cell renal cell carcinoma (CC-RCC) is the most let

159 ppressor protein pVHL is commonly mutated in clear cell renal cell carcinoma (ccRCC) and has been imp

160 f flux balance analysis in two cancer types, clear cell renal cell carcinoma (ccRCC) and prostate ade

161 tin 3 (TRPM3) channel promotes the growth of clear cell renal cell carcinoma (ccRCC) and stimulates M

162 inically, SCP1 and SCP3 are downregulated in clear cell renal cell carcinoma (ccRCC) and these events

163 scular area mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The C

164 In agreement, SETD2-mutant clear cell renal cell carcinoma (ccRCC) cells displayed

165 The presence of sarcomatoid features in clear cell renal cell carcinoma (ccRCC) confers a poor p

166 Clear cell renal cell carcinoma (ccRCC) has been previou

167 ysregulation of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncover

168 However, its role in clear cell renal cell carcinoma (ccRCC) has not been des

169 Recent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered n

170 Clear cell renal cell carcinoma (ccRCC) is a gender-bias

171 nd a T cell infiltration score and find that clear cell renal cell carcinoma (ccRCC) is among the hig

172 Clear cell renal cell carcinoma (ccRCC) is an aggressive

173 Clear cell renal cell carcinoma (CCRCC) is an incurable

174 Clear cell renal cell carcinoma (ccRCC) is characterized

175 Clear cell renal cell carcinoma (ccRCC) is characterized

176 Clear cell renal cell carcinoma (CCRCC) is characterized

177 Clear cell renal cell carcinoma (ccRCC) is cytogenetical

178 Clear cell renal cell carcinoma (ccRCC) is histologicall

179 Clear cell renal cell carcinoma (ccRCC) is the most comm

180 Clear cell renal cell carcinoma (ccRCC) is the most comm

181 Clear cell renal cell carcinoma (ccRCC) is the most comm

182 Clear cell renal cell carcinoma (ccRCC) is the most comm

183 Human clear cell renal cell carcinoma (ccRCC) is therapy resis

184 in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and fiv

185 tion factor (HIF) signaling pathway promotes clear cell renal cell carcinoma (ccRCC) progression and

186 ncer arising from the kidney in adults, with clear cell renal cell carcinoma (ccRCC) representing app

187 iptional profiling of a cohort of 50 primary clear cell renal cell carcinoma (ccRCC) samples from The

188 1) was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which w

189 Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromati

190 On the other hand, clear cell renal cell carcinoma (ccRCC) strongly deviate

191 oit novel compounds with high selectivity to clear cell renal cell carcinoma (ccRCC) with common muta

192 genesis is an important prognostic factor of clear cell renal cell carcinoma (ccRCC), as well as a fa

193 In the most common form of RCC, clear cell renal cell carcinoma (ccRCC), inactivation of

194 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogeno

195 Clear cell renal cell carcinoma (ccRCC), the most common

196 ted as an early event in almost all cases of clear cell renal cell carcinoma (ccRCC), the most freque

197 For clear cell renal cell carcinoma (ccRCC), three of the fi

198 ints-average sensitivity and specificity for clear cell renal cell carcinoma (ccRCC)-were compared be

199 six tandem BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

200 outcomes for African American patients with clear cell renal cell carcinoma (ccRCC).

201 dau (VHL) gene mutations are associated with clear cell renal cell carcinoma (ccRCC).

202 ection of miR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).

203 s a direct transcriptional target of HIFs in clear cell renal cell carcinoma (ccRCC).

204 eases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC).

205 mor suppressor VHL, the most common event in clear cell renal cell carcinoma (ccRCC).

206 major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC).

207 rface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

208 odeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC).

209 genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC).

210 rimethyltransferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is u

211 C is frequently inactivated in patients with clear cell renal cell carcinoma (ccRCC); however, it is

212 ancer subtypes from The Cancer Genome Atlas: clear cell renal cell carcinoma (ccRCC, also known as ki

213 gle-agent targeted therapies in advanced non-clear cell renal cell carcinoma (ncRCC) compared with cl

214 in zebrafish and murine xenograft models of clear cell renal cell carcinoma (RCC) and pancreatic ade

215 Clear cell renal cell carcinoma (RCC) is considered an i

216 l renal cell carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study

217 e revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC).

218 pVHL-defective clear cell renal cell carcinoma cell lines display unexp

219 Intriguingly, clear cell renal cell carcinoma cells (ccRCC) have a dys

220 Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification o

221 els of primary and metastatic pVHL-defective clear cell renal cell carcinoma in an on-target fashion.

222 ur recurrence after nephrectomy in localised clear cell renal cell carcinoma is well characterised by

223 Clear cell renal cell carcinoma masses are more likely t

224 roarray samples from tumors of patients with clear cell renal cell carcinoma shows that increased CDC

225 with treatment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between Se

226 A total of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned e

227 of 626 patients from France with stage I-III clear cell renal cell carcinoma who had also undergone n

228 cal outcome in 942 patients with stage I-III clear cell renal cell carcinoma who had undergone a neph

229 papillary, chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previ

230 ulation by the transcription factor HNF4A in clear cell renal cell carcinoma, despite no differential

231 glioma multiforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate ca

232 linical outcome in patients with stage I-III clear cell renal cell carcinoma, providing a more accura

233 mmune infiltrates in lung adenocarcinoma and clear cell renal cell carcinoma, respectively.

234 In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved prog

235 Clear cell renal cell carcinoma, the most common form of

236 L diseases, including sporadic and inherited clear cell renal cell carcinoma.

237 to improve prediction of recurrence risk in clear cell renal cell carcinoma.

238 eptor inhibitor, in patients with metastatic clear cell renal cell carcinoma.

239 r remains the optimal approach in metastatic clear cell renal cell carcinoma.

240 tor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma.

241 n an attempt to delay disease progression in clear cell renal cell carcinoma.

242 More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactiv

243 essor gene is inactivated in the majority of clear cell renal cell carcinomas (ccRCC), but genetic ab

244 VHL-deficient clear cell renal cell carcinomas (ccRCC), the most commo

245 VEGF, which drives abnormal angiogenesis in clear cell renal cell carcinomas (ccRCC).

246 Clear cell renal cell carcinomas (ccRCCs) are characteri

247 Clear cell renal cell carcinomas (ccRCCs) display diverg

248 A subset of familial and sporadic clear cell renal cell carcinomas (ccRCCs) is believed to

249 suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to in

250 mors that included renal oncocytomas and non-clear cell renal cell carcinomas (nccRCCs), consisting o

251 Clear cell renal cell carcinomas (RCC) frequently displa

252 Clear cell renal cell carcinomas (RCC), the major histol

253 Non-clear cell renal cell carcinomas are histologically and

254 tute a significant portion of aggressive non-clear cell renal cell carcinomas that have no standard t

255 Clear-cell renal cell cancer (CRCC) is initiated typical

256 Clear-cell renal cell carcinoma (ccRCC) is a common aggr

257 Importantly, clear-cell renal cell carcinoma (ccRCC) is frequently as

258 Surgery for clear-cell renal cell carcinoma (ccRCC) might benefit fr

259 n and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models.

260 von Hippel-Lindau (VHL) are major causes of clear-cell renal cell carcinoma (ccRCC) that may origina

261 In clear-cell renal cell carcinoma (ccRCC), inactivation of

262 ad to benign and malignant tumors, including clear-cell renal cell carcinoma (ccRCC).

263 or the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC).

264 med metastatic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (

265 years and older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and

266 r suppressor pVHL is lost in the majority of clear-cell renal cell carcinomas (RCC).

267 lysis, we assessed 145 patients with primary clear-cell renal-cell carcinoma and defined PBRM1 and BA

268 Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor r

269 sphorylated STAT3 are remarkably elevated in clear-cell renal-cell carcinoma relative to adjacent nor

270 is for a molecular genetic classification of clear-cell renal-cell carcinoma that could influence tre

271 ed 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma to receive either suniti

272 ndings identify mutation-defined subtypes of clear-cell renal-cell carcinoma with distinct clinical o

273 covered that BAP1 is mutated in about 15% of clear-cell renal-cell carcinoma, and that BAP1 and PBRM1

274 Clear-cell renal-cell carcinomas display divergent clini

275 rolled patients with advanced or metastatic, clear-cell, renal cell carcinoma.

276 ] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) carcinomas (

277 5% CI, 1.08 to 1.46) but a decreased risk of clear cell (RR, 0.72; 95% CI, 0.55 to 0.94) tumors (P-he

278 6 odds ratio (OR)=1.13, P=3.1 x 10(-10)) and clear cell (rs11651755 OR=0.77, P=1.6 x 10(-8)) epitheli

279 Clear cell sarcoma (CCS) of tendons and aponeuroses is a

280 81 inhibited the growth of a patient-derived clear cell sarcoma cell line whose oncogenic potential i

281 a, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal ca

282 terminus of BCOR in 23 of 27 (85%) pediatric clear cell sarcomas of the kidney (CCSK) from two indepe

283 Clear cell-specific clinical trials based upon these bio

284 , ranging from 106 to 2238 CNV segments in a clear-cell specimen and in a papillary type 2 specimen,

285 cally verified renal tumors: 9 patients with clear cell subtype of the renal cell carcinoma, 5 patien

286 odine concentration and tumor grade for both clear cell (tau = 0.85; P < .001) and papillary RCC rena

287 n were only associated with endometrioid and clear cell tumors (P-het </= .01).

288 are the most prevalent molecular features of clear cell tumors.

289 Validation in a bigger cohort of clear-cell tumors of the ovary is warranted.

290 lated, expressed HNF1B, primarily present in clear cell tumours, coincides with a CpG island methylat

291 nt of metastatic renal cell carcinoma of the clear cell type.

292 ograft models of renal cell carcinoma of the clear cell type.

293 Renal cell carcinoma of clear-cell type (ccRCC) is an enigmatic tumor type, char

294 Renal cell carcinoma (RCC) of clear-cell type (ccRCC), the most common type, begins wi

295 e four most commonly mutated genes in RCC of clear-cell type (the most common type) are two-hit tumor

296 of ccRCC precursor lesions, including cysts, clear cell-type cells, and dysplasia.

297 The clear cell variant (ccRCC) is the most common and aggres

298 The clear cell variant constitutes a relatively small histol

299 orts an obesity paradox in patients with the clear cell variant; however, population-based cohort dat

300 very unusual, pathologically proven case of clear cell variety of pediatric RCC which showed invasio